Bill Lundberg

Sven Ante Lundberg is currently an Independent Director at Q32 Bio, Inc. since 2024 and a Director at Q32 Bio Operations, Inc. Former roles include President, CEO & Executive Director at Merus NV from 2023 to 2025; Independent Director at Vor Biopharma, Inc. from 2019 to 2025; Chief Scientific Officer at CRISPR Therapeutics AG from 2015 to 2018; Vice President & Head-Translational Medicine at Alexion Pharmaceuticals, Inc. from 2011 to 2015; Director & Chief Medical Officer at Taligen Therapeutics, Inc. from 2010 to 2012; Medical Director at Wyeth LLC and Genzyme Corp.; Director at Alliance for Regenerative Medicine; Principal at Antisoma Research Ltd. and Antisoma, Inc.; and Vice President-Clinical Development at Sarossa Capital Ltd. Education includes undergraduate studies at Massachusetts Institute of Technology, MBA degrees from the University of Massachusetts and The Isenberg School of Management, and a doctorate from Stanford University School of Medicine.